POLA1 and diffuse large B-cell lymphoma: Another report (6) described favorable therapeutic response of DLBCL–type methotrexate-associated lymphoproliferative disorder (MTX-LPD, stage IV, high-risk, non-GCB subtype) with six cycles of the Pola–R–CHP.